Stable patterns, shifting risks: the impact of British Columbia’s decriminalization and recriminalization policies on drug use behaviours
Ali, F., Mende-Gibson, J., Russell, C., Torres-Salbach, S., Bardwell, G., Bonn, M., Budau, J., Ivsins, A., and Rehm, J., Harm Reduction Journal
Extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose: The FASTER-BUP udy
Socias ME, Dickhout P, Langlois J, Grant C, Nolan S., Drug Alcohol Depend. 2025
Sharing drug checking results in a Canadian setting: a multi-site analysis
Bird J, Tobias S, Grant C, Lysyshyn M, Tupper K, Wood E, Kerr T, Ti L., Int J Drug Policy. 2025
Impact of having a regular drug dealer on obtaining drug checking results consistent with expectations during a drug toxicity crisis in a Canadian setting
Esopenko H, Marshall BDL, Lysyshyn M, Grant C, Sherman SG, Wood E, Kerr T, Ti L., Drug Alcohol Depend. 2025
Concordance Between Urine Drug Screening and Self-Reported Use in the Context of a Pragmatic Randomized-Controlled Trial in People with Prescription-Type Opioid Use Disorder: Concordance entre le dépistage de drogues dans l’urine et l’usage autodéclaré dans le contexte d’un essai pragmatique contrôlé à répartition aléatoire chez des personnes présentant un trouble lié à l’usage d’opioïdes vendus sur ordonnance
Bastien G, Abboud A, McAnulty C, Mahroug A, Le Foll B, Socias ME, Juteau LC, Dubreucq S, Jutras-Aswad D., Can J Psychiatry. 2025
Exploring unregulated substance use health data in Ontario, Canada: Identifying gaps, addressing challenges, and uncovering opportunities
Ali, F., Law, J., Russell, C., Imtiaz, S., Bayoumi, A., Werb, D., Rhem, J., Front. Public Health
Trends in stimulant use among patients with opioid use disorder receiving substance use treatment: Findings from a prospective cohort study from 2013 to 2020
Jackson E, Bach P, Socias ME, Brooks OM, Fairbairn N, Rodrigues M, Rosic T, Naji L, Jinks-Chang S, Nolan S, Chesney A, Reshetukha T, Samaan Z, Dennis BB., Drug Alcohol Depend. 2025
Indigenous peoples and medications for opioid use disorders: A scoping review
Gala N, Dobischok S, Bernett P, Parker DG, O’Callahan A, Zentner D, Huson K, Tomaro J, Wendt DC., Psychol Addict Behav. 2025
Characterizing changes to harm reduction site operations in British Columbia following the implementation of the decriminalization of drugs: Findings from a provincial survey
Ali, F. , Russell,C., Law, J., Imtiaz, S., Budau, J., Shahin, R., MacKinnon, L., Griffith, S., Patenaude, S., Xavier, J., Rhem, J., Harm Reduction Journal
Capacity Building and Creating Supportive Environments for Inclusive Community-Based Participatory Research: A Case Study of the Overdose Prevention Peer Research Assistant (OPPRA) Project
Morgan J, Taylor T, Nolan S, Blais A, Cywink SL, Duguay JM, Gibbons TA, Maxwell S, Marsh S, Pratt M, Glegg S, Int J Qual Methods, 2025.
